{"id":583153,"date":"2022-01-24T09:42:01","date_gmt":"2022-01-24T09:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=583153"},"modified":"2022-01-24T09:42:01","modified_gmt":"2022-01-24T09:42:01","slug":"chlamydia-infections-pipeline-therapies-drugs-clinical-trials-analysis-report-2021-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chlamydia-infections-pipeline-therapies-drugs-clinical-trials-analysis-report-2021-delveinsight_583153.html","title":{"rendered":"Chlamydia Infections Pipeline, Therapies, Drugs, Clinical Trials Analysis Report 2021 | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1641456603.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Chlamydia Infections Pipeline, Therapies, Drugs, Clinical Trials Analysis Report 2021 | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1641456603.jpeg\" alt=\"Chlamydia Infections Pipeline, Therapies, Drugs, Clinical Trials Analysis Report 2021 | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Chlamydia Infections Pipeline<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s <strong>&ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chlamydia-infections-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Chlamydia Infections Pipeline Insight<\/a>&rdquo;<\/strong> report provides comprehensive insights about&nbsp;10+&nbsp;companies and&nbsp;10+&nbsp;pipeline drugs in the Chlamydia Infections pipeline landscapes. It comprises Chlamydia Infections pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Chlamydia Infections therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Chlamydia Infections pipeline products.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key takeaways from the&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chlamydia-infections-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Chlamydia Infections Pipeline Report<\/a>&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Major companies such as&nbsp;Abera Bioscience AB, Spixia Biotechnology, Prokarium, QURETECH BIO, Evofem Biosciences, Abivax SA, Eurocine Vaccines AB, Genetic Immunity Inc., Vault Pharma, Yaso Therapeutics,&nbsp;and others are developing potential drug candidates to improve the Chlamydia Infections treatment scenario.&nbsp;<\/li>\n<li>EVO100&nbsp;has been granted&nbsp;Fast Track Designation&nbsp;for Chlamydia prevention in women. It is designated a&nbsp;Qualified Infectious Disease Product (QIDP)&nbsp;to prevent gonorrhea in women by the U.S. Food and Drug Administration.<\/li>\n<li>In September 2018,&nbsp;BlueWillow Biologics&nbsp;announced the company had been awarded an NIH&nbsp;Small Business Innovation Research (SBIR) grant to develop&nbsp;an intranasal&nbsp;NanoVax&reg;&nbsp;vaccine to prevent chlamydia. More than 131 million new chlamydia infections worldwide each year, and no approved vaccine currently exists to prevent the infection.<\/li>\n<li>QURETECH BIO&nbsp;is developing&nbsp;Chlamydia Infection Blockers. These are the Virulence blockers that can replace antibiotics for the treatment of chlamydia infections. They are currently in the preclinical stage of development.<\/li>\n<li>In February 2021,&nbsp;Eurocine Vaccines AB&nbsp;(&ldquo;Eurocine Vaccines&rdquo;) confirms good immunological effect in a preclinical animal study with its chlamydia vaccine candidate. The study demonstrates that an adapted variant of the vaccine, designed to meet the regulatory requirements for a finished product, is highly immunogenic. The good immunological effect of the tested vaccine surpasses, by a good margin, what in previous studies with our vaccine has protected in preclinical models.<\/li>\n<li>On March 31, 2021,&nbsp;Eurocine Vaccines AB&nbsp;(&ldquo;Eurocine Vaccines&rdquo;) announced the completion of knowledge transfer and preparations for the development of the manufacturing process to secure the active protein needed in the toxicological and clinical studies with the company&acute;s chlamydia vaccine candidate and the start of process development activities.<\/li>\n<li>Genetic Immunity Inc. is developing&nbsp;ChlamyDerm Immune Therapy&nbsp;against Chlamydia infection that plays a role in atherosclerosis. They have demonstrated in mice the decrease of both inflammation and Chlamydia bacterium in the lung after ChlamyDerm immunization.<\/li>\n<li>In March 2019, Yaso Therapeutics&nbsp;announced that the company had received a fifth&nbsp;SBIR grant&nbsp;from the National Institutes of Health (NIH), enabling the firm to complete preclinical testing of a novel polymer,&nbsp;PPCM&nbsp;contraceptive, multi-purpose prevention drug product.&nbsp; Preclinical studies of PPCM indicate it is both contraceptive and can prevent various diseases, including herpes, gonorrhea, and chlamydia.&nbsp;&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get an overview of pipeline landscape @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chlamydia-infections-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Chlamydia Infections Clinical Trials Analysis<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Chlamydia can infect both men and women. Chlamydial Infections are treated primarily by administering antibiotics such as Azithromycin, Doxycycline, Ofloxacin.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/chlamydia-infections-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\"><strong>Chlamydia Infections Emerging Drugs<\/strong><\/a><\/p>\n<ul style=\"text-align: justify;\">\n<li>&nbsp;EVO100: Evofem Biosciences<\/li>\n<\/ul>\n<ul style=\"text-align: justify;\">\n<li>Chlamydia Vaccine Candidate: Eurocine Vaccines AB<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Eurocine Vaccines AB is developing a Chlamydia Vaccine Candidate. They have successfully identified sections of the MOMP (Major Outer Membrane Protein) in the bacterium Chlamydia trachomatis &ndash; sequences that can be used to stimulate an immune response. The specially designed protein chains are essential for the creation of the vaccine and are patent protected.<\/p>\n<p style=\"text-align: justify;\">Research and DevelopmentInitial studies have proven the active protein to be very immunogenic and well-tolerated even without an adjuvant.Three major pre-clinical studies have been performed in mice, resulting in positive antibody and T-cell responses. The current development involves; 1) setting up an industrially scalable manufacturing process to ensure high-quality supply to future studies &ndash; 1st &ndash; 4th quarter 2021; 2) to manufacture study products for the planned clinical study according to GMP &ndash; 2nd quarter 2022; and 3) to design a Phase I clinical trial to be started in the fall of 2022.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">For further information, refer to the detailed report @&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/chlamydia-infections-pipeline-insight?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\" target=\"_blank\">Chlamydia Infections Pipeline Therapeutics<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of&nbsp;Chlamydia Infections Pipeline Drug Insight&nbsp;&nbsp;&nbsp;&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage:&nbsp;Global&nbsp;<\/li>\n<li>Major Players: 10+ Key Players<\/li>\n<li>Prominent Players:&nbsp;Abera Bioscience AB, Spixia Biotechnology, Prokarium, QURETECH BIO, Evofem Biosciences, Abivax SA, Eurocine Vaccines AB, Genetic Immunity Inc., Vault Pharma, Yaso Therapeutics<\/li>\n<li>Key Drugs Profiles: 10+ Products<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Questions regarding&nbsp;Current Chlamydia Infections Treatment Landscape&nbsp;and Emerging Therapies Answered in the Pipeline Report &nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>What are the current options for Chlamydia Infections treatment?<\/li>\n<li>How many companies are developing therapies for the treatment of Chlamydia Infections?&nbsp;<\/li>\n<li>How many are Chlamydia Infections emerging therapies in the early-stage, mid-stage, and late development stages to treat Chlamydia Infections?&nbsp;<\/li>\n<li>What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Chlamydia Infections market?&nbsp;<\/li>\n<li>Which are the dormant and discontinued products and the reasons for the same?<\/li>\n<li>What is the unmet need for current therapies for the treatment of Chlamydia Infections?&nbsp;&nbsp;<\/li>\n<li>What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Chlamydia Infections therapies?&nbsp;<\/li>\n<li>What are the critical designations that have been granted for the emerging therapies for Chlamydia Infections?&nbsp;<\/li>\n<li>How many patents are granted and pending for the emerging therapies to treat Chlamydia Infections?&nbsp; &nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents<\/strong><\/p>\n<table border=\"0\" cellpadding=\"0\">\n<tbody>\n<tr>\n<td>\n<p>1<\/p>\n<\/td>\n<td>\n<p>Chlamydia Infections Report Introduction<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>2<\/p>\n<\/td>\n<td>\n<p>Chlamydia Infections Executive Summary<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>3<\/p>\n<\/td>\n<td>\n<p>Chlamydia Infections Overview<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>4<\/p>\n<\/td>\n<td>\n<p>Chlamydia Infections &ndash; DelveInsight&rsquo;s Analytical Perspective In-depth Commercial Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>5<\/p>\n<\/td>\n<td>\n<p>Chlamydia Infections Pipeline Therapeutics<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>6<\/p>\n<\/td>\n<td>\n<p>Chlamydia Infections Late Stage Products (Registered)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>7<\/p>\n<\/td>\n<td>\n<p>Chlamydia Infections Late Stage Products (Phase III)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>7.1<\/p>\n<\/td>\n<td>\n<p>EVO100: Evofem Biosciences<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>8<\/p>\n<\/td>\n<td>\n<p>Chlamydia Infections Mid Stage Products (Phase II)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>9<\/p>\n<\/td>\n<td>\n<p>Chlamydia Infections Early Stage Products (Phase I)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>10<\/p>\n<\/td>\n<td>\n<p>Chlamydia Infections Pre-clinical and Discovery Stage Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>10.1<\/p>\n<\/td>\n<td>\n<p>VPI-201: Vault Pharma<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>11<\/p>\n<\/td>\n<td>\n<p>Chlamydia Infections Therapeutic Assessment<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>12<\/p>\n<\/td>\n<td>\n<p>Chlamydia Infections Inactive Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>13<\/p>\n<\/td>\n<td>\n<p>Company-University Collaborations (Licensing\/Partnering) Analysis<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>14<\/p>\n<\/td>\n<td>\n<p>Chlamydia Infections Key Companies<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>15<\/p>\n<\/td>\n<td>\n<p>Chlamydia Infections Key Products<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>16<\/p>\n<\/td>\n<td>\n<p>Chlamydia Infections Unmet Needs<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>17&nbsp;<\/p>\n<\/td>\n<td>\n<p>Chlamydia Infections Market Drivers and Barriers<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>18<\/p>\n<\/td>\n<td>\n<p>Chlamydia Infections Future Perspectives and Conclusion<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>19<\/p>\n<\/td>\n<td>\n<p>Chlamydia Infections Analyst Views<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>20<\/p>\n<\/td>\n<td>\n<p>Appendix<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n<p>21<\/p>\n<\/td>\n<td>\n<p>About DelveInsight<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides&nbsp;Healthcare Consulting&nbsp;services comprising credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=chlamydia-infections-pipeline-therapies-drugs-clinical-trials-analysis-report-2021-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/chlamydia-infections-pipeline-insight\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/chlamydia-infections-pipeline-insight<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/chlamydia-infections-pipeline-insight\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=chlamydia-infections-pipeline-therapies-drugs-clinical-trials-analysis-report-2021-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Chlamydia Infections Pipeline DelveInsight&rsquo;s &ldquo;Chlamydia Infections Pipeline Insight&rdquo; report provides comprehensive insights about&nbsp;10+&nbsp;companies and&nbsp;10+&nbsp;pipeline drugs in the Chlamydia Infections pipeline landscapes. It comprises Chlamydia Infections pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Chlamydia Infections &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/chlamydia-infections-pipeline-therapies-drugs-clinical-trials-analysis-report-2021-delveinsight_583153.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-583153","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/583153","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=583153"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/583153\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=583153"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=583153"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=583153"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}